Talazoparib + enzalutamide beneficial in metastatic prostate cancer
by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according
Updated on: December 17,2023
10

Talazoparib + enzalutamide beneficial in metastatic prostate cancer
by Elana GotkineFor patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according
Updated on:December 17,2023
10
